This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 25, 2013

Primary Completion Date

January 22, 2014

Study Completion Date

January 22, 2014

Conditions

Prostatic Hyperplasia

Interventions

DRUG

Dutasteride and Tamsulosin

0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C

Trial Locations (1)

GSK Investigational Site, Shanghai